New pill aims to slow lung scarring in IPF patients
NCT ID NCT07284459
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests an experimental pill called PIPE-791 in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 324 adults aged 40 and older will receive either the drug or a placebo to see if it helps preserve lung function. The main goal is to measure changes in breathing capacity over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Anil Dhar Medicine Professional Corporation
RECRUITINGWindsor, Ontario, N8X 5A6, Canada
-
Dynamic Drug Advancement Ltd.
RECRUITINGAjax, Ontario, L1S 2J5, Canada
Conditions
Explore the condition pages connected to this study.